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Extended-spectrum -lactamases (ESBL) of the CTX-M, SHV, and TEM families were recognized in 76
(67%), 31 (27%), and 6 (5%) isolates, respectively, among 162 ESBL-producing Klebsiella pneumoniae (ESBL-
Kp) strains obtained in a multicenter study in Spain. Predisposing factors for ESBL-Kp acquisition included
invasive procedures, mechanical ventilation, and previous antimicrobial use.
Extended-spectrum -lactamases (ESBL) currently represent a
major problem, antibiotic resistance in enterobacteria (20). Dur-
ing the last decade, strains of both Escherichia coli and Klebsiella
pneumoniae producing CTX-M enzymes (particularly CTX-M-
15) have been increasingly isolated on all continents (1, 5–7, 9, 10,
15–17). In a multicenter study on ESBL-producing E. coli and
ESBL-producing K. pneumoniae (ESBL-Kp) carried out in 2000
in Spain (12, 13), the mean prevalence of ESBL production in K.
pneumoniaewas 2.7%. The most common enzymes detected were
TEM-derived -lactamases, and only three isolates producing
CTX-M enzymes (specifically CTX-M-10) were identified (12).
A multicenter study was repeated in 2006 (1 February to 31
March) (GEIH-BLEE-2006) (8). Consecutively obtained K.
pneumoniae strains from clinical samples (1 per patient) with an
ESBL production phenotype were obtained in 44 centers. Organ-
isms were confirmed to be K. pneumoniae with API 20E strips
(bioMe´rieux, France). Confirmation of ESBL production and
testing of susceptibility to aztreonam, cefepime, cefpodoxime,
ceftriaxone, cefoxitin, cefotetan, imipenem, and meropenem were
performed with ESBL-Plus panels (Microscan; Dade). Suscepti-
bility to other agents indicated in Table 1 was determined by
broth microdilution according to CLSI guidelines (3). Clinical
categories were defined according to the 2010 document from the
CLSI (4).
Clonal relationships of the isolates were determined by re-
petitive extragenic palindromic PCR (REP-PCR) as described
elsewhere (2). Pulsed-field gel electrophoresis (PFGE) (14, 21)
was also performed for 29 organisms from the two centers with
more than 10 isolates and for 56 isolates presenting identical
REP-PCR patterns isolated in different centers or with just one
single band of difference. Transmission of resistance by conju-
gation to E. coli J-53 (azide resistant) was evaluated according
to REP-PCR/PFGE patterns, including (i) all isolates repre-
senting patterns with single isolates, (ii) one isolate of every
different antibiogram type (4-fold difference in the MICs of
at least two agents of different biochemical groups) for pat-
terns including 2 to 4 isolates, and (iii) two isolates of every
different antibiogram type (as defined above) for patterns in-
cluding 5 isolates. Selection was done on plates containing
either cefotaxime (2 mg/liter) or ampicillin (100 mg/liter).
ESBL production was confirmed in transconjugants by disk
diffusion (disks from Oxoid, United Kingdom) according to
CLSI guidelines (4). -Lactamase genes were detected by PCR
and sequencing in the parental isolates selected for conjuga-
tion studies or in derived transconjugants, using previously
described primers and conditions for TEM (19), SHV (19),
and CTX-M (18) enzymes. CTX-M groups were determined
according to the method of Woodford et al. (22). CTX-M-15
was differentiated from CTX-M-28 by PCR as described pre-
viously (13a). Epidemiological and clinical data from patients
in whom ESBL-producing Klebsiella pneumoniae (ESBL-Kp)
was isolated were collected using a structured questionnaire.
ESBL-Kp strains isolated after 48 h of hospital admission were
considered nosocomially acquired (NA) (11). Among the rest,
ESBL-Kp strains were considered health care associated
(HCA) if the patient was admitted to an acute- or long-term-
care center or received hemodialysis, specialized home care, or
care in a day hospital during the preceding 3 months. All other
isolates were considered to be community acquired (CA).
Qualitative variables were compared using the chi-square test
or the Fisher exact test as appropriate. The project was ap-
proved by the Ethic Committee of the Hospital Universitario
Virgen Macarena, which waived the need for informed consent
due to the observational nature of the study.
ESBL-Kp strains were isolated in 32 out of the 44 (72.7%)
participating centers. In all, 162 isolates (1 to 16 per center),
corresponding to 80 clones (1 to 9 per center), were obtained. A
predominant clone was present in a specific hospital in most
cases, although in 12 and 8 centers, 3 and 2 clones were iden-
tified, respectively.
The results of susceptibility testing are presented in Table 1.
One (0.6%) isolate was susceptible to cefotaxime, 7 (4.3%) and 12
(7.4%) isolates were intermediate and susceptible to ceftazidime,
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respectively, 14 (8.6%) and 13 (8.0%) were intermediate and
susceptible to cefepime, respectively, and 4 (2.5%) and 11 (6.8%)
were intermediate and susceptible to aztreonam, respectively.
However, whether the patients from whom ESBL-Kp strains sus-
ceptible to expanded-spectrum cephalosporins or aztreonam
were isolated may respond satisfactorily when treated with these
agents is not yet completely defined. Carbapenems were very
active, and only 2 (1.2%) and 1 (0.6%) isolates were resistant and
intermediate to ertapenem, respectively. Amikacin and tigecy-
cline also presented good in vitro activity against the tested iso-
lates. ESBL-Kp isolates in Spain in 2006 were more resistant than
the isolates studied in 2000 to amoxicillin-clavulanate, piperacil-
lin-tazobactam, ciprofloxacin, and co-trimoxazole (Table 1). In-
creased resistance to amoxicillin-clavulanate might be related to
the dissemination of plasmids coding for CXT-M-15 (see below)
that usually also contain other determinants of resistance to this
combination. The decreased activity of ciprofloxacin may be re-
lated in part to the presence of aac(6)-Ib-cr, which was detected
in 34.2% of 114 isolates studied (unpublished data).
In 2006, ESBL were identified in 105 out of the 114 (92.1%)
isolates. The ESBL identified in 2006 clearly differ from those
observed in 2000 (12, 13). An SHV amplicon was obtained in
107 (93.8%) of these 114 parental isolates, but an SHV-type
ESBL was identified in only 31 isolates, of which 21 contained
SHV-12, 6 contained SHV-2, 3 contained SHV-5, and 1 con-
tained SHV-33. The remaining 76 SHV amplicons presumably
correspond to the non-ESBL variants of the chromosomal
SHV enzyme of K. pneumoniae. Sequencing in 37 randomly
chosen isolates from which SHV-type enzymes were not iden-
tified in transconjugants confirmed in all cases the presence of
either SHV-1 (21 isolates; 56.8%) or SHV-11 (16 isolates;
43.2%). A gene coding for a TEM enzyme was detected in 55
(48.2%) out of the 114 parental isolates, but a TEM-type
ESBL was demonstrated in only 6 (5.3%) transconjugants
(TEM-4 in 3 cases and TEM-3, TEM-15, and TEM-74 in 1 case
each). Sequencing of the gene in the remaining 49 cases dem-
onstrated the presence of TEM-1. Genes coding for CTX-M
ESBL were detected in 76 (66.7%) of the 114 isolates, with the
following distribution: CTX-M-15 genes in 40 isolates, CTX-
M-1 genes in 15 isolates, CTX-M-14 genes in 14 isolates, CTX-
M-32 genes in 4 isolates, and CTX-M-9 genes in 3 isolates.
Isolates with CTX-M-15 were present in 18 hospitals, and
those with SHV-12 were present in 14 centers. CTX-M-14 and
CTX-M-1 were also broadly distributed (each enzyme in
strains from 8 centers). This distribution of ESBL among K.
pneumoniae strains mirrors that obtained in the E. coli strains
isolated during the same period (9).
ESBL-Kp strains were obtained from 133 adults and 29
pediatric patients (of whom 26 were from neonates). Complete
clinical data were available for 102 adults and 23 neonates
(Table 2). Acquisition was considered nosocomial for 85 (64%)
adult patients admitted to medical services (35 patients), sur-
gical services (25 patients), or intensive care units (ICUs) (25
patients). Acquisition of the pathogen was health care associ-
ated for 28 (21%) adults (22 received specialized ambulatory
care, 10 had previous hospital admission, 3 were nursing home
residents, and 1 was on hemodialysis). For the remaining 17
(13%) adults, a strict community origin was considered. One
hundred three out of the 133 (77%) adult patients were con-
sidered to have an infection. Clustered isolates were more
frequently nosocomial than nonnosocomial (77% versus 59%;
P  0.01), while sporadic isolates were more frequently strictly
community acquired than health care related or nosocomial
(17% versus 6%; P  0.01). The most frequent ESBL in adults
were CTX-M-15 (47 isolates), SHV-12 (29 isolates), and CTX-
M-14 (18 isolates). Empirical therapy was inappropriate in
about half of adult patients. However, since our series included
TABLE 1. In vitro activities of antimicrobial agents against ESBL-producing K. pneumoniae isolates in the
GEIH-BLEE-2006 study (n  162)a
Agent
MIC (mg/liter) % susceptible isolates
Range 50% 90% 2006 study 2000 studyb
Cefotaxime 0.5–128 128 128 0.6 —
Ceftazidime 0.5–128 128 64 7.4 —
Cefepime 1–32 32 32 8.0 —
Aztreonam 0.5–64 64 64 6.8 —
Cefoxitin 2–32 4 16 87.1 94
Cefotetan 1–4 1 1 100 98.5
Imipenem 0.5–1 0.5 0.5 100 100
Meropenem 0.5–2 0.5 0.5 100 100
Ertapenem 0.008–16 0.125 0.5 98.2 Not tested
Amoxicillin-clavulanatec 8–128 64 128 4.3 40
Piperacillin-tazobactamd 1–1,024 16 1,024 55.6 74
Nalidixic acid 2–1,024 1,024 1,024 28.0 Not tested
Ciprofloxacin 0.008–128 32 128 37.8 88.5
Gentamicin 0.125–128 8 128 49.4 33.0
Tobramycin 0.125–128 16 64 35.9 38.5
Amikacin 0.25–64 1 8 98.1 91.0
Tigecycline 0.008–8 0.5 4 Not applicable Not tested
Co-trimoxazolee 0.062–32 32 32 27.2 40.0
a Susceptibility defined by 2010 CLSI breakpoints (4). Data on percentages of susceptibility from isolates obtained in the study performed in 2000 (n  70) are also
presented for comparison.
b —, not determined (all organisms considered resistant because of ESBL production).
c The concentrations of amoxicillin are indicated.
d The concentrations of piperacillin are indicated.
e The concentrations of trimethoprim are indicated.
VOL. 49, 2011 NOTES 1135
 o
n
 January 29, 2016 by INSTITUTO
 DE PARASITO
LO
G
FA Y
http://jcm.asm.org/
D
ow
nloaded from
 
many patients with noninvasive infections (mostly cystitis),
mortality in this series was low.
Acquisition of ESBL-Kp was considered to be nosocomial for
all neonates, of which 23 (88%) were considered to be infected.
Among neonates, the most frequent ESBL was again CTX-M-15
(19 patients). Clusters of related isolates were found in 5 of 7
neonatal units with cases. This study confirms the relevant role of
ESBL-Kp as a pathogen in neonatal units. The fact that most
neonates received appropriate therapy (mostly carbapenems) in-
dicates a high level of suspicion within units affected by outbreaks.
However, such extensive use of carbapenems might facilitate the
spread of carbapenem resistance, and thus control of ESBL-Kp
within neonatal units should be considered a priority.
The study group GEIH-BLEE-2006 (Spain) is represented by C. Mar-
tínez Peinado (Villajoyosa, Alicante), J. F. Orda´s (Cangas de Nancea,
Asturias), E. Gardun˜o (Badajoz), M. A. Domínguez (Barcelona), F. Na-
varro (Barcelona), G. Prats (Barcelona), F. Marco (Barcelona), E. Ojeda
(Burgos), P. Marín (Ca´diz), R. Carranza (Alcazar de San Juan, Ciudad
Real), F. Rodríguez (Co´rdoba), C. García Tejero (Figueras, Gerona), F.
Artiles (Gran Canaria), B. Palop (Granada), I. Cuesta (Jae´n), M. Cartelle
(A Corun˜a), M. D. Rodríguez (Ferrol, A Corun˜a), I. Ferna´ndez (Leo´n),
E. Ugalde (Logron˜o), R. Canto´n (Madrid), E. Cercenado (Madrid), F.
Chaves (Madrid), J. J. Picazo (Madrid), A. Delgado (Alcorco´n, Madrid),
C. Guerrero (Murcia), B. Ferna´ndez (Orense), A. Fleites (Oviedo), A.
Oliver (Palma de Mallorca), J. J. García (Pamplona), M. García (Pon-
tevedra), J. Elías (Salamanca), L. Martínez-Martínez (Santander), M.
Trevin˜o (Santiago de Compostela), M. Ruiz (Seville), M. A. Díaz
(Seville), M. Lara (Tenerife), L. Torres (Teruel), E. García (Toledo), D.
Navarro (Valencia), M. Gobernado (Valencia), A. Tenorio (Valladolid),
I. Otero (Vigo), L. Michaus (Vitoria), and J. Castillo (Zaragoza).
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TABLE 2. Sites of infection, therapies, and prognoses of 127
patients with infection due to ESBL-producing K. pneumoniae
Variable Adults(n  104)
Neonates
(n  23)
No. (%) of patients with:
Infection type
Urinary tract 50 (49)a 9 (39)
Respiratory tract 32 (22)b 5 (22)
Skin and soft tissue 19 (18)c 1 (5)
Primary bacteremia 7 (7) 5 (22)
Other 3 (3)d 1 (5)e
Appropriate empirical therapy 58 (56) 14 (88)
Median hospital stay after
infection (no. of days
interquartile range)
24 (13–47) 19 (5–40)
Mortality during admission
(no. % of patients)
14 (14) 2 (9)
a Infections were cystitis (n 48), prostatitis (n 1), and pyelonephritis (n 1).
b Infections included pneumonia (n  14) and tracheobronchitis (n  9).
c Infections were cellulitis (n  11), chronic ulcer infection (n  7), and
necrotizing cellulitis (n  1).
d Infections were osteomyelitis (n  2) and cholangitis (n  1).
e Intra-abdominal infection.
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